Dana F Flavin, MD, MS

ICRM Instructor & Founding Member

Born in Chicago as the youngest child of Dr. and Mrs. Byron Flavin. Both parents studied Medicine and their excellent example of compassion and devotion to duty made a lasting impression on Dr. Flavin‟s life. Her continuous education in Science and Medicine has helped her to find and improve therapies for many diseases including Cancer, Autoimmune diseases such as Graves thyroiditis, rheumatoid arthritis and viral diseases. She received her first degree in Psychology and Chemistry from Loyola University in 1972 and then began graduate school in Pharmacology at Chicago Medical School. After 4 years and part I of her Medical Boards, she was appointed Science Assistant to the Associate Bureau Director for Toxicology at the Food and Drug Administration in Washington D.C.

During this time she researched the Molecular Biology of Cancer and Tumor Promotion investigating the application of Translational Medicine into potential therapies for cancer. She then was appointed Science Advisor to the President of the Nutrition Foundation and began graduate studies at Howard University in Nutrient Biochemistry under the Department of Nutrition. Several years later with summa cum Laude in Nutrition she moved to Germany and began her studies in Medicine for completion of her M.D. degree in Innsbruck, Austria, including years devoted to research.

Dr. Flavin was exposed to the traumas of illness early in her life when her father suffered a stoke leaving him partially paralyzed and without sufficient health insurance. She was 15 at the time. One year later, she herself suffered Epileptic seizures following a mild brain injury. She lost part of her vocabulary and alphabet recognition. The illness was treated with heavy medication for several years until it was found to be completely cured. In spite of all this she had straight A's in Biology in High School. At age 20, she was admitted into the hospital for a breast tumor. She was told they may have to perform a radical mastectomy. It was removed and fortunately found to be benign but one of a type that could, over time, have become malignant. Nine months later, she broke her neck in an automobile accident, leaving her in a hospital bed for 6 months. She was in a stryker frame with screws in her skull to stabilize her and she was unable to move . During this time she took additional reading courses for her degree. She had a Plexiglas table made so she could read lying down, since she was unable to walk or sit up until the vertebrae were later fused with an operation and then 12 weeks in a body cast. She was greatly influenced by the suffering in the Neurology department around her in Mercy Hospital for those six months and aware of her good fortune to be able to walk out on her own without paralysis. She realized the brain cancer patients she had met would not go home. That many in a coma would not be able to lead normal lives and that those paralyzed would not walk.

This is what started her devotion to help patients with illnesses and to relieve suffering and find cures.

 

CURRICULUM VITAE


EDUCATION:
 

Innsbruck, Austria

Leopold Franzens University: Doctor of Medicine 1999

Medicine/Biochemical Pharmacology 1999


Munich, Germany

Technical University Medical School: Doctor of Medicine 1996


Washington, D. C., USA

Howard University, MS Nutrition/Biochemistry, summa cum laude 1986

Georgetown University Medical School Gross Anatomy, Honors 1975


Chicago, IL, USA

Chicago University, Finch University of Health Sciences Pharmacology, Ph.D. Candidate1975

Loyola University BS Psychology/Chemistry 1972

 

Medical Training Bad Heilbrunn,Germany

Internal Medicine/OncologyLeonardis Oncology Klinik 2000-2004

 

Berg, Germany

SurgeryStarnberg Community Hospital 1998

General Medicine Dr. Reinhard Luyken Private Practice 1993

Internal/Intensive MedicineArgirov Klinik 1993

PsychiatryRottmannshoehe Heckscher Klinik 1992

 

PROFESSIONAL POSITIONS:


The Foundation for Collaborative Medicine and Research Washington, D. C., USA 2001-present

Founding Director


Flavin Pharmaceuticals, Inc Greenwich, CT 2008

Chairman


Dancour, LLC Greenwich, CT 2009

Chairman


IMRAC, Haus Burkstetten Berg, Germany 1999

International Medical Research & Consulting


Bristol Myers Squibb Brussels, Belgium 1999

Oncology/Advisor


Novartis Consumer Health (Ciba-Geigy) Nyon, Switzerland 1997 - 1998

Medical/ Scientific Advisor

New Drug research and Development


BASF Ludwigshafen, Germany 1987 - 1989

Science Consultant

Vitamins and cancer


The Nutrition Foundation Washington, D. C. 1982 - 1985

Science Advisor to the President


Food and Drug Administration Washington, D. C.1979 - 1982

Science Assistant to the Associate Bureau Director for Toxicology 1980 - 1982

Pharmacologist 1979 - 1980


Warren - Teed PharmaceuticalsColumbus, Ohio 1978 - 1979

Sales and Marketing Representative


Consultant , Science/ Pharmacology Washington, D. C.1975 - 1978


Morris And Ward Consultants 1977 - 1978


Southeast Community Hospital1975 - 1977

 

PATENTS:

U. S., Patent Application Viral Hepatitis Treatment. 531,3001980

Germany, Patent Registration Combination Preparation for Viral diseases. 103 40 845.22004

Rheumabehandlung/Arthritis Treatment.Patent Pending2004

 

LANGUAGES: 

Fluent: English, German, Spanish

 

COMPANY CONSULTATION AND PRESENTATIONS:

BASF -  Nutrients and Cancer Prevention

Novartis - Viral toxicities and Therapies

Roche Pharmaceuticals - New Cancer Therapy Development

Bionorica - Phytopharmacology and Disease Treatment

Bristol Myer Squibb - Translational Oncology

Pfizer - Mechanism or Cancer Growth and Immune Suppression

 

TARGETED THERAPIES:

Autoimmune Disease Therapy with Natural Substances (Book). (In Revisal, copyright, 2000)

Medical Treatments and Support Therapies Developed:

Epstein Barr Virus, Hepatosplenomegalies cured in 24 - 28 hours.

HBV, Inhibition of liver toxicity,

HIV, Increase in T - cells and general health.

Asthma, total elimination of steroid needs.

Colitis Ulcerosa, Elimination of steroids and all conventional medicines.

Rheumatoid Arthritis, total elimination of steroids and other conventional medicines.

Multiple Sclerosis. Elimination of relapses, steroid needs, and conventional medicines in 99% of cases.

Lupus Erythematosus, Elimination of steroids, and most conventional medicine.

Morbus Crohn, Elimination of steroids and conventional medicines in 85% of cases.

Graves Disease: reduced antibodies (TRAb) and Thyroid values to normal in 3 weeks.

Hashimotos: Reduced antibodies 90% in 4 weeks (TPO). No more symptoms of fatigue etc.

Cancer therapies:

Cervix cancer cured in 6 months using all natural substances.

Ovarian carcinoma with plura metasases totally reduced in 3 months, accompanying therapy carboplatin and Cyclophosphamide. No side effects from chemo.

Colon cancer (adenocarcinoma) total remission, liver lung and lymph metastases gone in 3 months, CT clear, accompanying therapy 5FU. No side effects from chemo

Breast cancer with 30 brain metastases totally reduced in 10 weeks, still in remission over three years.

Acute myelogenous leukemia in total remission with chemotherapy, no side effects from chemo

Non Hodgkins Lymphoma three month reversal with natural therapies.

 

ABSTRACTS:

I.D. F. Flavin. Tryptamine Receptors in the Frog Heart Ventricle. Sigma Xi, 1973

II.W. A. Pedemonte, D. F. Flavin, H. C. Sabelli. Indolacetate Activation of Tryptamine Receptors in the Frog Heart. The Pharmacologist 15 (2), 135, 1973

III.D. F: Flavin. Behavioral and Electrophysiological Effects of Phenylethanolamine - A Putative Neurotransmitter. Sigma Xi, 1974.

IV.D. F. Flavin - Koenig. What Do We About Orthomolecular Therapy? 34. Medicine week Conference. Baden - Baden, Germany, 2000.

 

PRESENTATIONS:

Indolacetate activation of Tryptamine Receptors in the Frog Heart.American Society for Pharmacology and Experimental Therapeutics. Eastern Michigan University. Ypsilanti, Michigan, 1973.

Behavioral and Electrophysiological effects of Phenylethanolamine, a Putative Neurotransmitter. Sigma Xi, Chicago Medical School. Chicago, Illinois, 1974.

The Effects of Pargyline on the Electrical Activity of the Membrane. George Washington University. Washington, D. C., 1980.

Your Body’s Future. Nutrition and Health, World Future Society, Washington, D.C. Chapter, 1981.

Multiple Modalities in Tumor Prevention and Treatment. Cancer Conference. University of Arizona. Tucson, Arizona, 1982.

Cancer Prevention. Hillside Hospital, Livingston Clinic. San Diego, California, 1982.

Nutritional Alterations in the Biochemistry of Tumor Promotion. F.D.A. Washington, D.C., 1982.

Nutritional Effects in Tumor Promotion. Institut Suisse de Experimentale sur le Cancer, ISREC. Epalinges sur Lausanne, Switzerland, 1983.

Nutrition and Cancer. American International Hospital. Zion, Illinois, 1983.

Nutritional Factors that Inhibit Tumor Promotion. North Carolina State University. Raleigh, North Carolina, 1984.

Nutrients in Cancer Prevention. Instituto Superiore di Sanita. Rome, Italy. 1984.

Nutrients and Oxygen Radical Interactions in Tumor Promotion. National Institute of Health National Cancer Institute. Bethesda, Maryland, 1985.

Molecular Changes in Tumor Promotion and Relationship to Oxygen radicals.Gesellschaft für Strahlen - und Umweltforschung (Radiation Research Center). Munich, Germany, 1987.

Nutritional Prevention in Cancer. National Congress on Nutrition and Cancer. Trieste, Italy, 1988.

Antioxidants in Cancer Prevention. International Association of Vitamins and Nutritional Oncology. Charleston, South Carolina, USA, 1989.

Oxygen Radicals in Neurological Toxicity. Neurology Disease Conference, All India Institute for Medical Research. New Delhi, India, 1991.

Oxygen Radicals in Liver Disease. Oxygen Radical Conference, Semmelweis University. Budapest, Hungary, 1993.

New Treatments in Hepatitis, Technical University Medical School/Glaxo Wellcome. Munich, Germany, 1994.

Xanthine Oxidase and Nitric Oxide Synthase in Viral Disease: Reversal of Hepatosplenomegaly in EBV Infected Children in 24 - 48 Hours. LMU/ GroBhadern Hospital, MED POLY II, 1994.

Immune Modulation in Viral Hepatitis Treatments, New Drug Development. ESSEX Pharm. Munich, Germany, 1995.

New Viral Treatments. Developments for Future Pharmacological Applications. Novartis/Ciba - Geigy. Nyon, Switzerland, 1997.

The Role of Nitric Oxide Synthase in Disease and Toxicity. Boehringer Mannheim/Hoffman - La Roche. Penzberg, Germany, 1997.

New Concepts in Drug Development: The Mechanism of Natural Inhibitors of Viral Replication and Toxicity. Bionorica, Arzneimittel, Neumarkt, Germany, 1999

What Do We Know About Orthomolecular Therapy, Cancer: Replication & Immune Suppression Mechanisms of Nutrient Supplements, 34 Medicine Week Conference, Baden - Baden, Germany, 2000.

Integrated Therapy in Cancer Treatment, Cross Talking at the Cellular Level. Centro Prevenzione Salute. Livorno, Italy, February 16, 2002.

The Application of Natural Substances in Tumor Therapy: The Oncology Patient. Community Hospital at Hall, in Tirol (Sponsor). Hilton Hotel, Innsbruck, Austria, Nov 9, 2002.

Integrated Therapy in Cancer Treatment, Cross Talking at the Cellular level. Centro Prevenzione in Oncologie. Giornata Internazionale di Studio, Attualita E Prospettive. Rome, Italy, Nov 13, 2003.

Health Forum Conference, Nutrients and Nutrition in Cancer Prevention and Treatment.Hilton Hotel, Munich, Germany, June 3, 2004.

Integrative Medizin in der Onkologie, Leonardis Klinik, Bad Heilbrunn Germany: “Increased Response in Cancer Therapy through Molecular biology”, October 16, 2004.

Prevention instead of Intervention, Leonardis Klinik, Bad Heilbrunn, Germany

“Multifactoral Preventive Measures against Cancer”, June 25, 2005.

Nutritients in Cancer Therapy. C.A.R.E. Meeting, Methodist church. Ridgewood, New Jersey, November 10, 2005.

Understanding Cancer, International Research in Therapy. C.AR.E Meeting, December 8, 2005.

Preventing Cancer, Cos Cob Library, Cos Cob CT, April 2007.

Anti Cancer and Anti Aging, Greenwich Library, Greenwich CT.May, 2007

 

PUBLICATIONS:

1. Differential Effects of Two Putative Neuromodulators, 2 - Phenylethylamine and Phenylethanolamine. H. C. Sabelli, A.J. Vasquez, and D. F. Flavin. The Society of Neuroscience, 1974.

2. Behavioral and Electrophysiological Effects of Phenylethanolamine and 2 - Phenylethylamine. H.C. Sabelli, A.J. Vasquez, and D. F. Flavin. Psychopharmacologia, 42 (2), 117 - 125, 1975.

3. Cimetidine, an Antihistaminic. D. F. Flavin. Monograph for the American Society of Hospital Pharmacists, January, 1978.

4. Neurobehavioral Test Outline for Drug and/or Chemical Toxicity Studies and Evaluations. D. F. Flavin. Division of Toxicology, F.D.A., February, 1979.

5. Carcinogens and Steroid Receptors. D. F. Flavin. Harvard Magazine, Letter, 1981.

6. The Effects of Soybean Trypsin Inhibitor on the Pancreas of Animals and Man. Review. D. F. Flavin. Veterinary and Human Toxicology, 24, 25 - 28, 1982.

7. Nutritional factors with the Potential to Inhibit Critical Pathways of Tumor Promotion. D. F. Flavin, A. C. Kolbye, Jr. in Modulation and Mediation of Cancer by Vitamins (eds., F. L. Meyskens, K. N. Prasad) pp. 24 - 32, Karger, Basel, Switzerland, 1983.

8. Generalized Cellular Toxicity in Toxic Hyperplasia and Tumor Promotion. D. F. Flavin and C. J. Carr. Appendix C, Response By the Nutrition Foundation, Inc. to the Office Science and Technology Policy: Chemical Carcinogens, Notice of Review of the Science and its Associated Principles, Federal Register Draft Document, May 22, 1984.

9. Toxicity, Tumor Promotion and Carcinogenesis in Relation to Excessive Dosage. D. F. Flavin, Regulatory Toxicology and Pharmacology, 4, 372 - 379, 1984.

10. Cancerous Esoterous. D. F. Flavin, in Advances in Free Radicals, Biology and Medicine, (ed. W. A. Pryor) Academic Press, Vol. 2, 445 - 451, 1986.

11. The Role of Putative Chemopreventive Nutrients, Retinoids, Tocopherols, Ascorbic Acid, and Selenium, in Cancer Induction. D. F. Flavin, (summa cum Laude) Masters Thesis, Howard University, Washington, D. C., 1986.

12. A Common Enemy (Peroxynitrite). D. F. Flavin - Koenig, The New Zealand Medical Journal, Vol. 108, pg. 89, 1995.

13. The reversal of Epstein Barr Virus Induced Hepatosplenomegaly in 24 Hours with Inhibitors of Xanthine Oxidase and Nitric Oxide Synthase. D. F. Flavin - Koenig and W. Tschollar, The New Zealand Medical Journal, 22 March, pg. 106 - 107, 1996.

14. What Do We Know About OrthomolecularMedicine?: Cancer: Replication and Immune suppression, Mechanisms of Nutrient Supplements. 34. Medizinische Woche, 28. October to 3 November, (Karl F. Haug Verlag, in MVH Medizinverlage Heidelberg Gmbh & Co. KG,) Manuscript accepted. 2000/2001.

15. Reversing Splenomegalies in Epstein Barr Virus Infected Children: Mechanisms of toxicity in Viral diseases, Dana F. Flavin, The Journal of Orthomolecular Medicine, Second Quarter, 21:2, Pg 95-101, 2006.

16. A Lipoxygenase Inhibitor in Breast Cancer Brain Metastases, D.F.Flavin, J Neurooncology, 82:91-93, 2007.

 

POSTERS:

a)The Reversal of Hepatosplenomegaly in EBV infected children

b)Gesellschaft fur Strahlen Forschung , Dr. med Dana F. Flavin - König

c)Neuherberg ,Germany, 1996.

d)Annual Conference Effect of Lactoferrin in Cancer and G.I. Diseases: Dr. D. F. Flavin - Koenig and Massimo Bonucci. Capri, Italy, May 2003.

 

RADIO INTERVIEWS:

WBAI New York. February 2005, July 2005, November 2005, December 2005.

Television InterviewsCBN News, The Toxicity of Corn Syrup, Feb 4, 2009.

 

AWARDS: 

Women of Innovation in Science and Medicine, Connecticut Technology Council, January 30, 2008